BRIEF-Alpha Cognition Inc - On Track And Plans To Release Data From Alpha-1062 Pivotal Trial During Q2 Of 2022
BRIEF-Alpha Cognition Inc - On Track And Plans To Release Data From Alpha-1062 Pivotal Trial During Q2 Of 2022
簡要-Alpha Cognition Inc-正在進行中，並計劃在2022年第二季度發佈Alpha-1062關鍵試驗的數據
May 31 (Reuters) - Alpha Cognition Inc ACOG.V :
路透5月31日電-Alpha Cognition Inc ACOG.V：
* ALPHA COGNITION INC - ON TRACK AND PLANS TO RELEASE DATA FROM ALPHA-1062 PIVOTAL TRIAL DURING Q2 OF 2022
*阿爾法認知公司-正在進行中，並計劃在2022年第二季度發佈阿爾法-1062關鍵試驗的數據
* ALPHA COGNITION INC - PLANS TO MEET WITH FDA FOR ALPHA-1062 INTRANASAL FOR MTBI DURING Q3 OF 2022
*阿爾法認知公司-計劃在2022年第三季度就阿爾法-1062鼻腔MTBI與FDA會面
* ALPHA COGNITION INC - Q1 2022 NET LOSS WAS $2.7 MILLION, OR A NET LOSS OF $0.04 PER SHARE
*阿爾法認知公司-2022年第一季度淨虧損270萬美元，或每股淨虧損0.04美元
* ALPHA COGNITION INC - CASH, CASH EQUIVALENTS AS OF MARCH 31, 2022, WERE $9.1 MILLION
*阿爾法認知公司-截至2022年3月31日的現金、現金等價物為910萬美元
Source text for Eikon: ID:nBw2kCFj7a Further company coverage: ACOG.V
Eikon的源文本：ID：nBw2kCFj7a進一步的公司報道：ACOG.V